-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) reported a net loss of $23.62 million or $0.70 per share for the third quarter of
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG): Q3 2019 Earnings Snapshot
Categories
pharmaceuticals
Rite Aid swings to profit in Q2, stock gains strength
Pharmacy retailer Rite Aid Corporation (NYSE: RAD) swung to a profit in the second quarter of 2020, from a loss in the year-over
Ovid Therapeutics stock gains on positive epilepsy trial data
Ovid Therapeutics Inc. (NASDAQ: OVID) stock climbed to an 8-month high of $3.05 on Tuesday after positive initial data from rare epilepsies
Wall St expecting a turn-around quarter from Rite Aid in Q2
Things haven’t been working out so well for Rite Aid (NYSE: RAD) since the past three years. The company’s inability to stop
Will Zynerba Zygel trial be extended amid safety warning?
Zynerba Pharmaceuticals (NASDAQ: ZYNE) stock retreated on Wednesday after serious adverse events in phase 2 clinical trial of transdermal cannabidiol gel, Zygel.
Three companies that are haunted by multiple lawsuits
Several companies have battled lawsuits from time to time for various reasons. However, sometimes companies face thousands of lawsuits for one reason.
Alexion Pharmaceuticals could still be a valuable addition to your portfolio
Biopharmaceutical firm Alexion Pharmaceuticals (NASDAQ: ALXN) has been going through a volatile phase lately. The company was expected to be the takeover
Lundbeck to acquire Alder BioPharmaceuticals for $1.95 billion; Alder stock hits new 52-week high
Denmark-based biopharma company Lundbeck announced today that it will acquire Alder BioPharmaceuticals (NASDAQ: ALDR) for $1.95 billion. Alder stock, which reached a
Will Allergan-AbbVie merger be intercepted
Allergan plc (NYSE: AGN) continued to dominate in the tissue expander market as the demand for plastic surgeries is increasing from the
Catalyst Pharmaceuticals stock soars to record high
Catalyst Pharmaceuticals (NASDAQ: CPRX) stock soared to a record high of $7.67 on Wednesday as phase 3 trial results date is nearing
Novartis scores another point in multiple sclerosis therapy, stock rises
Swiss pharmaceutical giant Novartis International AG (NYSE: NVS) on Friday said its ofatumumab met the primary and secondary endpoints of Phase 3
Exelixis surpasses Q2 earnings estimate by 6 cents
Exelixis Inc. (NASDAQ: EXEL) reported second-quarter earnings of 29 cents per share, down 6.4% year-over-year. The bottom line surpassed the average analysts’
Vertex Pharmaceuticals Q2 profit jumps 29%, beats estimates
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported a 29% jump in earnings for the second quarter of 2019 helped by strong growth in
ACADIA Pharmaceuticals Q2 results beat estimates, raises outlook
ACADIA Pharmaceuticals (NASDAQ: ACAD) stock soared 5% in the after-market trading hours as the biopharma firm reported better-than-expected Q2 results. The company
Amarin’s stock gains on Q2 results beat
Amarin Corporation plc (NASDAQ: AMRN) reported better-than-expected revenue and earnings for the second quarter of 2019, allowing the stock to gain 2.2%
Pfizer’s stock suffers as Q2 results and Mylan deal fail to impress Wall Street
Pfizer Inc.’s (NYSE: PFE) shares continue to trade in red after the company narrowly missed revenue estimates for the second quarter of
Celgene Q2 profit beats estimates, lifts FY19 guidance
Celgene Corporation (NASDAQ: CELG) reported a 50% jump in earnings for the second quarter of 2019 helped by higher revenue as well
Merck rises on oncology strength post Q2 earnings
Shares of pharmaceutical giant Merck (NYSE: MRK) rose 3% before the market hours on Tuesday after the company reported second-quarter results that
Eli Lilly Q2 profit beats estimates, lifts FY19 forecast
Eli Lilly and Company (NYSE: LLY) swung to a profit in the second quarter of 2019 from a loss last year, helped
Earnings preview: What to look for when Gilead reports Q2 results
Gilead Sciences Inc. (NYSE: GILD) is scheduled to report second quarter 2019 earnings results on Tuesday, July 30, after market close. Analysts
Sanofi slips to a loss in Q2 on Eloctate impairment charge
Sanofi (NASDAQ: SNY) slipped to a loss in the second quarter of 2019 from a profit last year, due to a EUR1.8